Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04249583 · ClinicalTrials.gov registry record · Phase 3
Treatment of Moderate to Severe Glabellar Lines
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT04249583 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 300 participants.
The verdict
NCT04249583, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL botulinum toxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2020-02-10 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04249583
The ClinicalTrials.gov registry entry for NCT04249583 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04249583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04249583 about?
NCT04249583 is a clinical study titled "Treatment of Moderate to Severe Glabellar Lines". The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.
What is the current status of trial NCT04249583?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2020-02-10. Estimated completion is 2021-01-05.
What interventions are being tested in trial NCT04249583?
The interventions under investigation include: Placebo (BIOLOGICAL), botulinum toxin (BIOLOGICAL).
Who is sponsoring clinical trial NCT04249583?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.